InvestorWire NewsRoom


InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Third Quarter Numbers, Notes Q3 Investor Day
July 29, 2021

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Third Quarter Numbers, Notes Q3 Investor Day

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, has reported its interim financial results; the results cover the three- and nine-month period ended May 31, 2021. Highlights of the report include Tryp’s collaboration with the Chronic Pain & Fatigue Research Center at the University of Michigan Medical School; the two companies will work together to conduct a Phase 2a clinical trial for fibromyalgia that is the first Phase 2 study evaluating the efficacy of a psychedelic compound for the indication. In addition, Tryp also partnered with the University of Michigan and George Mashour, MD, PhD, to focus on the development of Tryp’s proprietary, psilocybin-based TRP-8803 drug product. TRYP is also working with Fluence on the design and implementation of innovative psychotherapy to be used with Tryp’s psilocybin-based drug compounds and Alcami to develop analytical methods and final formulations for Tryp’s drug products. Other corporate highlights for the company included the appointment of Robin Carhart-Harris, PhD, as chair of Tryp’s Scientific Advisory Board (“SAB”), as well as the addition of Daniel Clauw, MD, to the board. Financial numbers for the period ending May 31, 2021, include total assets of $6.1 million and net and comprehensive losses of $2.6 million. The company is also hosting a third-quarter virtual Investor Day, scheduled for July 29, 2021, at 9 a.m. PDT. Included on the event agenda will be a presentation by Tryp’s management team as well as a Q&A session. Tryp executives participating in the event include Greg McKee, chair and CEO; Luke Hayes, CFO; and Jim Gilligan, PhD, president and chief science officer. Interested individuals who are unable to attend can view a reply of the Investor Day on the company’s website for 30 days following the event.

To register for the event visit,

To view the full press release, visit

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and eating disorder indications. The company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).